Patents Assigned to VIB VZW
  • Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
    Patent number: 9234025
    Abstract: The present invention relates to an extracellular binding domain for an allosteric inhibitor, whereby said binding domain is derived from a single membrane span tyrosine kinase receptor. More specifically, the invention relates to an extracellular domain derived from a Fibroblast Growth Factor Receptor (FGFR). It further relates to the use of this domain for the identification of similar domains in the extracellular part of other tyrosine kinase receptors, and to a screening method for identification of a small compound allosteric inhibitor.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: January 12, 2016
    Assignees: SANOFI, VIB VZW, LIFE SCIENCES RESEARCH PARTNERS VZW, VRIJE UNIVERSITEIT BRUSSEL
    Inventors: Peter Carmeliet, Frederik De Smet, Joost Schymkowitz, Frédéric Rousseau, Corentin Herbert
  • Microorganisms genetically engineered to have modified N-glycosylation activity
    Patent number: 9222083
    Abstract: Described herein are methods and genetically engineered cells useful for producing an altered N-glycosylation form of a target molecule. Also described are methods and molecules with altered N-glycosylation useful for treating a variety of disorders such as metabolic disorders.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: December 29, 2015
    Assignees: Oxyrane UK Limited, VIB vzw, Universiteit Gent
    Inventors: Nico Luc Marc Callewaert, Wouter Vervecken, Karen Jacqueline Marcel De Pourcq, Steven Christian Jozef Geysens, Mouna Guerfal
  • Microorganisms genetically engineered to have modified N-glycosylation activity
    Patent number: 9206408
    Abstract: Described herein are methods and genetically engineered cells useful for producing an altered N-glycosylation form of a target molecule. Also described are methods and molecules with altered N-glycosylation useful for treating a variety of disorders such as metabolic disorders.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: December 8, 2015
    Assignees: Oxyrane UK Limited, VIB vzw, Universiteit Gent
    Inventors: Nico Luc Marc Callewaert, Wouter Vervecken, Karen Jacqueline Marcel De Pourcq, Steven Christian Jozef Geysens, Mouna Guerfal
  • EphA4 is a disease modifier in motor neuron disease
    Patent number: 9187784
    Abstract: The present application relates to the field of motor neuron diseases, most particularly to amyotrophic lateral sclerosis and spinomuscular atrophy. Provided herein are strategies to improve symptoms and increase survival in patients with these axonopathies by inhibiting signaling mediated by the EphA4 ephrin receptor.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: November 17, 2015
    Assignees: VIB VZW, Life Sciences Research Partners VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventor: Wim Robberecht
  • RESTORING PHOSPHORYLATION OF A NOVEL PINK1 SUBSTRATE TO TREAT PARKINSON'S DISEASE
    Publication number: 20150299672
    Abstract: The present application relates to the field of Parkinson's disease (PD), particularly sporadic PD or PD associated with mutations in the mitochondrial kinase PINK1. A new substrate for this kinase, NdufA10, is identified herein. In Parkinson's disease, this protein is dephosphorylated, which is linked to a loss of mitochondrial membrane potential. It is shown that restoring or mimicking phosphorylation of NdufA10 restores the phenotypic defects associated with Parkinson's disease and is thus a new therapeutic paradigm.
    Type: Application
    Filed: November 7, 2013
    Publication date: October 22, 2015
    Applicants: KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D, VIB VZW
    Inventors: Bart DE STROOPER, Patrik VERSTREKEN, Vanessa MORAIS EPIFÂNIO
  • Functional heavy chain antibodies, fragments thereof, library thereof and methods of production thereof
    Patent number: 9156905
    Abstract: The present invention relates to functional heavy chain antibodies, functional single domain heavy chain antibodies, functional VH domains, or functional fragments thereof comprising an amino acid which is neither a charged amino acid nor a C at position 45, and comprising an amino acid at position 103 independently chosen from the group consisting of R, G, K, S, Q, L, and P, and optionally an amino acid at position 108 independently chosen from the group consisting of Q, L and R, said positions determined according to the Kabat numbering.
    Type: Grant
    Filed: July 7, 2009
    Date of Patent: October 13, 2015
    Assignee: VIB vzw
    Inventors: Serge Muyldermans, Viet Khong Nguyen
  • Targeting and in vivo imaging of tumor-associated macrophages
    Patent number: 9101674
    Abstract: The invention relates to activities and characteristics of tumor-associated macrophages (TAMs). In particular, immunoglobulin single variable domains are provided against markers of TAMs, and methods using the same for in vivo imaging of tumor cells, as well as cancer diagnostics and therapeutics.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: August 11, 2015
    Assignees: VIB VZW, Vrije Universiteit Brussel
    Inventors: Kiavash Movahedi, Damya Laoui, Steve Schoonooghe, Geert Raes, Patrick De Baetselier, Jo Van Ginderachter, Nick Devoogdt, Tony Lahoutte
  • Genes involved in asymmetric cell division
    Patent number: 9102748
    Abstract: The present invention relates to a method to isolate genes involved in the process of asymmetric cell division. The invention relates further to genes isolated using this method, and their use in controlling root formation, preferably lateral root formation.
    Type: Grant
    Filed: August 28, 2006
    Date of Patent: August 11, 2015
    Assignees: VIB VZW, UNIVERSITEIT GENT
    Inventors: Tom Beeckman, Ive De Smet, Steffen Vanneste
  • Method for inducing protein aggregation using a polypeptide with an aggregation region
    Patent number: 9095556
    Abstract: The invention belongs to the field of functional proteomics and, more particularly, to the field of protein aggregation. Described are methods for interfering with the function of a target protein and uses a non-naturally, user-designed molecule, designated as interferor, that has a specificity for a target protein and that induces aggregation upon contact with the target protein. The invention also discloses such interferer molecules and their use in therapeutic applications.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: August 4, 2015
    Assignees: VIB VZW, VRIJE UNIVERSITEIT BRUSSEL
    Inventors: Joost Schymkowitz, Frederic Rousseau
  • Use of HUB1 polynucleotides for improving growth characteristics in plants
    Patent number: 9074006
    Abstract: The present invention relates generally to the field of molecular biology and concerns a method for improving various economically important growth characteristics in plants. More specifically, the present invention concerns inter alia a method for modifying growth characteristics in plants by modulating expression in a plant of a nucleic acid encoding a HUB1 (Histone Monoubiquitination 1) polypeptide or encoding another protein useful in the methods of the present invention. The modified growth characteristics comprise a modification of light regulated phenotypes, such as modified circadian clock and/or circadian clock responses, or modified plant architecture.
    Type: Grant
    Filed: July 29, 2009
    Date of Patent: July 7, 2015
    Assignees: BASF Plant Science GmbH, Universiteit Gent, VIB vzw
    Inventors: Kristiina Himanen, Maria Van Lijsebettens, Christophe Reuzeau, Tommaso Matteo Boccardi
  • Vaccine against infection
    Patent number: 9028844
    Abstract: The present invention relates to a vaccine against Trypanosoma cruzi infection, useful in the prevention and/or treatment of the Chagas disease. More specifically, the present invention relates to a recombinant mutant trans-sialidase enzyme that can be used as an efficient vaccine, without side effects.
    Type: Grant
    Filed: March 14, 2007
    Date of Patent: May 12, 2015
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Roland Contreras, Kristof De Vusser, Silvia Revelli
  • SINGLE DOMAIN ANTIBODIES CAPABLE OF MODULATING BACE ACTIVITY
    Publication number: 20150071940
    Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Application
    Filed: September 11, 2013
    Publication date: March 12, 2015
    Applicants: VIB VZW, VRIJE UNIVERSITEIT BRUSSEL, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D
    Inventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
  • BACE1 inhibitory antibodies
    Patent number: 8956614
    Abstract: The present invention relates to antibodies with a specificity for BACE1. More specifically, the invention provides monoclonal antibodies that bind to BACE1 and are capable of inhibiting the activity of BACE1 and methods producing these antibodies. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: February 17, 2015
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventors: Bart De Strooper, Lujia Zhou, Wim Annaert
  • RESPONSIVENESS TO ANGIOGENESIS INHIBITORS
    Publication number: 20150004136
    Abstract: The invention is concerned with a method of determining whether a patient is more suitably treated by a therapy with an angiogenesis inhibitor, such as bevacizumab, by determining the genotype of VEGFR-1 gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of VEGFR-1 gene. The invention further relates to a method for improving the treatment effect of chemotherapy of a patient suffering from cancer by adding an angiogenesis inhibitor, such as bevacizumab, based on the genotype of VEGFR-1 gene.
    Type: Application
    Filed: May 22, 2014
    Publication date: January 1, 2015
    Applicants: Hoffmann-La Roche Inc., VIB vzw
    Inventors: Peter Carmeliet, Sanne Lysbet de Haas, Diether Lambrechts, Stefan Scherer
  • DIAGNOSTIC TESTS FOR THE DETECTION OF INHERITED PERIPHERAL NEUROPATHIES
    Publication number: 20140356871
    Abstract: The disclosure relates to the field of human genetics, particularly the field of peripheral neuropathy, particularly inherited peripheral neuropathy. Specifically, the disclosure relates to methods and materials to detect hereditary peripheral neuropathy, more particularly autosomal recessive Charcot-Marie-Tooth disease.
    Type: Application
    Filed: January 10, 2013
    Publication date: December 4, 2014
    Applicant: VIB VZW
    Inventors: Albena Jordanova, Magdalena Zimon, Jonathan Baets, Peter De Jonghe
  • METHODS AND MEANS TO PRODUCE ABIOTIC STRESS TOLERANT PLANTS
    Publication number: 20140344996
    Abstract: This disclosure relates to the field of plant molecular biology and concerns methods for enhancing the abiotic stress tolerance in plants by modulating the expression of a gene involved in the gibberellin biosynthesis during the period of abiotic stress. This disclosure also provides chimeric constructs useful in the methods disclosed herein. In addition, transgenic plants having an enhanced abiotic stress resistance are provided herein.
    Type: Application
    Filed: September 14, 2012
    Publication date: November 20, 2014
    Applicant: VIB VZW
    Inventors: Dirk Gustaaf Inze, Marieke Dubois, Aleksandra Skirycz
  • Protein glycosylation modification in methylotrophic yeast
    Patent number: 8883445
    Abstract: The present invention provides genetically engineered strains of methylotrophic yeast including Pichia and especially Pichia pastoris capable of producing proteins with reduced or modified glycosylation. Methods of producing glycoproteins with reduced and/or modified glycosylation using such genetically engineered strains of Pichia are also provided. Vectors, which comprise coding sequences for ?-1,2-mannosidase I, glucosidase II, GlcNAc-tranferase I and mannosidase II or comprising OCH1 disrupting sequence, for transforming methylotrophic yeasts are contemplated by the present invention. Kit for providing the comtemplated vectors are also included in this invention.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: November 11, 2014
    Assignees: Research Corporation Technologies, Inc., Universiteit Gent, Vib, VZW
    Inventors: Roland Contreras, Nico L. M. Callewaert, Steven C. J. Geysens, Vladimir Kaigorodov, Vervecken Wouter
  • METHODS AND MEANS FOR GENERATING MICROBIAL DISEASE RESISTANT PLANTS
    Publication number: 20140325703
    Abstract: Described are genes and chimeric genes encoding anti-microbial peptides. These genes can be used to generate transgenic plants with an improved resistance to, for example, plant pathogenic fungi. Alternatively, the peptides encoded by these genes can be applied as agrochemical formulations to plants suffering from microbial diseases such as fungal diseases.
    Type: Application
    Filed: May 9, 2012
    Publication date: October 30, 2014
    Applicant: VIB VZW
    Inventors: Frank Van Breusegem, Annelies Inze, Janick Mathys, Bruno Cammue
  • METHOD FOR PREDICTING RISK OF HYPERTENSION ASSOCIATED WITH ANTI-ANGIOGENESIS THERAPY
    Publication number: 20140294811
    Abstract: The invention is concerned with a method of predicting a patient's susceptibility to developing hypertension associated with an anti-angiogenesis treatment, such as bevacizumab, by determining the genotype of KDR gene and/or EGF gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of KDR gene and/or EGF. The invention further relates to a method for reducing the risk of hypertension associated with an anti-angiogenesis therapy, such as bevacizumab, in a patient suffering from cancer by determining the genotype of KDR gene and/or EGF gene.
    Type: Application
    Filed: February 26, 2014
    Publication date: October 2, 2014
    Applicants: Hoffmann-La Roche Inc., VIB vzw, Life Sciences Research Partners vzw
    Inventors: Sanne Lysbet de Haas, Paul Delmar, Diether Lambrechts, Stefan Scherer
  • Cells producing glycoproteins having altered glycosylation patterns and method and use thereof
    Patent number: 8815580
    Abstract: The present application relates to the field of glyco-engineering, more specifically to eukaryotic cells wherein both an endoglucosaminidase and a glycoprotein are present. These cells can be used to deglycosylate or partly deglycosylate the (exogenous) glycoprotein, in particular without the need for adding an extra enzyme. Methods are also provided for the application of these cells in protein production. According to one specific aspect, the eukaryotic cells and methods are glyco-engineered yeast cells in which additionally at least one exogenous enzyme needed for complex glycosylation is present, e.g. allowing easier separation of differentially glycosylated glycoproteins.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: August 26, 2014
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Nico L. M. Callewaert, Karen De Pourcq, Steven Geysens, Leander Meuris